Novartis
$142.41Change from previous close: −0.11%Absolute change: −$0.16
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $270.51B
- Enterprise value
- $312.78B
- P/E (trailing 12 months)
- 21.5
- Forward P/E
- 14.5
- PEG
- 3.41
- Price/book
- 6.51
- Price/sales
- 4.77
- EV/EBITDA
- 13.5
- EV/revenue
- 5.52
Profitability and growth
- Gross margin
- 75.0%
- Operating margin
- 34.6%
- Net margin
- 22.5%
- ROE
- 30.4%
- ROA
- 10.3%
- Revenue growth (year over year)
- 0.8%
- Earnings growth (year over year)
- -17.0%
Financial health
- Total cash
- $7.62B
- Total debt
- $49.01B
- Debt/equity
- 1.17
- Current ratio
- 0.86
- Quick ratio
- 0.55
Dividends
- Annual dividend per share
- $4.74
- Dividend yield
- 3.3%
- Payout ratio
- 71.6%
- Ex-dividend date
- March 11, 2026
Analysts and estimates
- Average price target
- $156.29
- Median price target
- $160.15
- High price target
- $185.00
- Low price target
- $130.00
- Number of analysts
- 11
- Consensus
- Hold
- Forward EPS
- $9.84
- EPS estimate, current year
- $8.85
Shares and trading
- Beta
- 0.49
- Average volume
- 1.95M
- Shares outstanding
- 1.9B
- Float
- 1.86B
- Institutional ownership
- 7.3%
- Insider ownership
- 0.0%
- Short interest (% of float)
- 0.3%
- Short ratio (days)
- 2.19